August 22, 2019 Astra could use a voucher to cement roxadustat’s head start Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
July 26, 2019 Go or no go? Abbvie, Roche and Kala await key decisions One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
